He uncovered a $75K discrepancy and filed a complaint - then came the pink slip
A senior manager in AstraZeneca's US oncology unit alleges the company terminated him days after paying him the largest bonus of his seven-year career.
The complaint, filed October 5, 2026 in the US District Court for the District of Maryland, alleges the worker rose to Senior Manager on the Commercial Excellence team within the US Commercial Oncology business unit at AstraZeneca's Gaithersburg, Maryland facility. In seven years, according to the filing, he was never issued a written warning, placed on a performance improvement plan, or disciplined in any form.
Then things shifted.
The complaint alleges his direct manager began handing the worker's core duties to a colleague in a different role - someone who shared the manager's national origin. That included day-to-day oversight of a launch project management team the worker had trained and managed. The colleague, the filing states, also received leadership visibility and discrete responsibilities that fell within the worker's job description and had nothing to do with her own role.
The worker, meanwhile, was allegedly excluded from meetings and cut off from information he needed to do his job.
The filing draws a pointed comparison. The colleague's immediate predecessor held the identical position, in the same structure, under the same manager. That predecessor received none of the expanded authority or executive exposure. The sole material difference, according to the complaint: national origin.
The worker tried to escalate. In October 2024, the complaint alleges, he attempted to raise his concerns with a vice president under AstraZeneca's open-door policy. A director told him not to contact the VP and funneled him into HR's complaint process instead. The manager he was complaining about, according to the filing, kept direct personal access to that same VP throughout.
In December 2024, the worker submitted a formal complaint to HR, invoking AstraZeneca's own Code of Ethics. He asked for one thing: a different reporting line. According to the filing, AstraZeneca never responded to or acted on that request.
Then came the money.
In late 2024, the complaint alleges, a client flagged an approximately $75,000 discrepancy linked to the colleague. Before any investigation, according to the filing, the manager waved it off, stating in substance that "Enhertu has plenty of money." Four days after the worker submitted his formal HR complaint, a director assigned him to look into it.
The colleague allegedly stonewalled him - declining meetings, refusing to answer questions, and claiming leadership already had the information. The manager likewise declined to engage. The worker went directly to AstraZeneca's finance department and pulled the records himself.
When the colleague finally offered an explanation, according to the filing, she gave two that could not both be true: first that the charge was overtime, then that it was an accounting error. No refund or correction was made until the client escalated.
What followed, the filing alleges, was not accountability. The manager allegedly arranged - through separate meetings the worker was not part of - to consolidate the team under the same colleague. She emerged with expanded authority, reduced oversight, and additional staff. This came weeks after the confirmed discrepancy, and after she had obstructed the inquiry and offered contradictory explanations.
An alternate team was available, the complaint states. It had performed without incident and was not implicated. It was not chosen.
The worker's HR complaint had been open since October 2024. In early February 2025, roughly four months later, the complaint alleges AstraZeneca closed it as unsubstantiated. The closure notice, according to the filing, identified no witness interviewed, no document reviewed, and no investigative step taken.
When the worker told HR he was experiencing retaliation, the filing states, the response was: "I have no advice for you."
Two weeks later, the complaint alleges, the manager filed misconduct charges against the worker. His corroborating witness was the same colleague - the person whose conduct the worker had flagged and whose financial discrepancy he had investigated.
The timing, the filing states, was telling. The manager did not file the charges while the worker's complaint against him was still open. He filed them two weeks after it was closed.
The contrast in how AstraZeneca handled the two complaints, the filing alleges, was stark. The worker's four-month complaint closed with no evident investigation. The counter-charges against him produced a full Employee Relations investigation, written allegations, a formal response meeting, and a finding of policy violation - all within 23 days.
Among the allegations in the counter-charges, the complaint states, was the claim that the worker had intentionally excluded the colleague from meetings. According to the filing, no such meetings existed. The worker said so during his response meeting, and AstraZeneca's own calendar records confirm it.
On or about March 14, 2025, AstraZeneca terminated the worker.
Here is where the timeline gets hard to square. According to the filing, AstraZeneca paid the worker the largest bonus of his seven-year tenure in or about March 2025 - after the counter-charges, after the investigation, after the response meeting, and days before firing him. That same year, the complaint states, he received two Oncology Business Unit award nominations.
The worker brings six counts against AstraZeneca: national origin discrimination and retaliation under Title VII of the Civil Rights Act; discrimination and retaliation under the Civil Rights Act of 1866; a violation of Maryland's Fair Employment Practices Act; and discrimination, retaliation, and harassment under Montgomery County's human rights code. He is seeking back pay, front pay, compensatory and punitive damages, attorneys' fees, expungement of adverse references from his personnel file, and a jury trial.
For HR teams, the case puts a fine point on what happens when the subject of an internal complaint ends up driving the counter-charges - and when the investigation standards applied to each look nothing alike.
The allegations have not been tested, and no court has made any findings or rulings in this matter.
